ImmunityBio (IBRX) released updated Phase 2 data for their glioblastoma trial using ANKTIVA. The study focuses on patients with recurrent disease who failed standard treatments like surgery and chemo. Out of 23 enrolled patients, 19 are still alive. They haven't reached median overall survival yet, but the longest survivor is at 12 months so far. For context, the standard median survival for this specific group is usually around 6 to 9 months. The regimen is chemotherapy-free and aims to restore lymphocyte counts. They reported 3 serious adverse events related to the treatment but no cytokine release syndrome or neurotoxicity. They are planning randomized trials for both first and second-line patients next.